Solutions to optimize clinical outcome assessments to better measure drug efficacy and safety
Tools to detect patient cognitive impairment and change throughout the continuum of care
Technology for researchers studying cognition, from academics to public-private partnerships
Cogstate Ltd (ASX:CGS) is a leading neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerized cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture.
The company’s clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For more than 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world.
Cogstate’s innovative digital assessments are used worldwide to simplify the measurement of cognition. Our sensitive, rapid, and reliable computerized tests provide valuable brain health insights for researchers, physicians, and patients.
[Press Release]
[Press Release]
[Webinar]
[Webinar]
[Webinar]
[Press Release]
[Webinar]
[Financial Report]
[Webinar]
[Webinar]
[Resources]
[Webinar]
[Webinar]
[Webinar]
Please fill out the form to get in touch
